Minocycline ER spares the microbiome: A December JDD highlight
In the December issue of JDD we wanted to highlight a randomized, double‑blind, placebo‑controlled microbiome study of DFD‑29 (minocycline hydrochloride extended‑release 40 mg) given once daily for 16 weeks. Sixty healthy adults (2:1 randomization) had microbiologic sampling from forehead skin, stool and vagina at baseline and weeks 4, 8 and 16.
What did the authors find? No significant changes in microbial species abundance, no increase in minocycline resistance among colonizing organisms, and no rise in opportunistic microbes compared with placebo; there were also no safety signals of concern in this cohort.
These data provide reassuring short‑term safety on microbial communities for clinicians considering DFD‑29 as a rosacea option, though the study was in healthy volunteers over 16 weeks and may not capture subtle or longer‑term effects in treated patients.
For the full methods, subgroup analyses and practical implications for rosacea care, read the full captivating article.
J Drugs Dermatol. 2025;24(12):1222-1230. doi:10.36849/JDD.9245
Blog write-up assisted by AI
